ReviewFrontiers in medicine2025
Relationship between SPP1 (Osteopontin) and extracellular matrix dynamics: a comprehensive review.
Review in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Single-cell transcriptomics reveals that tenocyte-derived MIF contributes to tendon injury pathogenesis.iScience · 2026Article
- Matricellular Proteins in Bladder Cancer: Context-Dependent Roles in Tumor Promotion and Suppression.International journal of molecular sciences · 2026Review
- Prolonged high-density culture with restricted medium renewal induces epithelial-like plasticity in apical papilla stem cells.Biomolecules & biomedicine · 2026Article
- Learning heritable multimodal brain representation via contrastive learning.Research square · 2026Article
- Learning heritable multimodal brain representation via contrastive learning.bioRxiv : the preprint server for biology · 2026Article
- Electrochemical Biosensors for Cancer Diagnosis and Prognosis Using Protein Biomarkers: Current Trends, Advances, and Clinical Translation Potential.Sensors (Basel, Switzerland) · 2026Review
- Validation and Evaluation of SPP1 as a Candidate Biomarker for Disease Monitoring in Focal Segmental Glomerulosclerosis.International journal of nephrology and renovascular disease · 2026Article
- Identification and validation of key host genes associated with porcine H1N1 infection based on integrated machine learning algorithms.Frontiers in veterinary science · 2026Article
- The role of SPP1 in evaluating the prognosis, immune infiltration, and drug sensitivity of hepatocellular carcinoma.PloS one · 2026Article
- Tumor-associated macrophages in gastric cancer peritoneal metastasis: orchestrating immune evasion, niche remodeling, and therapeutic resistance.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Secreted Phosphoprotein 1 (SPP1), which encodes Osteopontin, a key member of the SIBLING family, is a multifunctional ECM glycoprotein and cytokine. Its interaction with collagen and other ECM components drives pathological remodeling across multiple diseases, yet a unified mechanistic framework remains elusive. Objective: This review synthesizes current evidence on SPP1-mediated ECM dysregulation, focusing on collagen deposition, epithelial-mesenchymal transition (EMT), and fibrosis, with the goal of elucidating its role as a central pathological hub. Methods: We synthesize the findings from multi-omics analyses (single-cell RNA sequencing, spatial transcriptomics), machine learning, and Conclusion: SPP1 is a master regulator of pathological ECM dynamics, driven by conserved SPP1
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.